Alphabet Inc Class A vs Immunovant Inc. Common Stock — how do they compare? Alphabet Inc Class A trades at $350.7 (market cap $4.27T), while Immunovant Inc. Common Stock trades at $30.01 (market cap $6.62B). The key difference: Alphabet Inc Class A is far larger — about 645× Immunovant Inc. Common Stock's market cap, and Alphabet Inc Class A pays a 0.25% dividend while Immunovant Inc. Common Stock pays none. Which is the better fit depends on your goals — on Pluang, investors hold Alphabet Inc Class A for 85 Days and Immunovant Inc. Common Stock for 0 Days on average.
| GOOGL | IMVT | |
|---|---|---|
Market Cap | $4.27T | $6.62B |
Volume | 20,474,140 | 1,131,364 |
Sector | Media | Health |
52-Week High | $402.62 | $44.96 |
52-Week Low | $236.59 | $17.03 |
Typical Hold Time | 85 Days | 0 Days |
Enterprise Value | $4.16T | $5.72B |
Dividend Yield | 0.25% | — |
Signals from Pluang's Aura AI — not financial advice
Alphabet (GOOGL) trades at $350.50, up 0.81% today, with a bullish technical signal and strong earnings beats in recent quarters. The stock shows robust fundamentals, including a 32.8% net income margin in 2025 and projected revenue growth to $445.9B in 2026. Analyst consensus is overwhelmingly positive, with an 86.75% buy rating and a $431.83 price target. Recent news highlights AI-driven growth opportunities and strategic partnerships.
The outlook for GOOGL remains favorable due to strong financial performance, AI integration, and analyst optimism. Key risks include regulatory scrutiny and market volatility. With solid cash flow and expanding profitability, the stock presents a compelling opportunity for growth-oriented investors, though attention to competitive and macroeconomic factors is advised.
No Aura AI signal available yet.
Trailing returns across standard periods
What Pluang investors did over the last 30 days
Latest headlines on both assets
Alphabet, the parent company of Google, earns nearly 90% of its revenue from Google services, mainly through advertising. Other revenue comes from subscriptions (YouTube TV, YouTube Music), platform sales (Play Store purchases), and devices (Pixel, Chromebooks, Chromecast). Google Cloud contributes around 10%, while investments in self-driving cars (Waymo), health (Verily), and internet access (Google Fiber) make up the rest.
Read more on GOOGL →Immunovant is a clinical-stage immunology company developing therapies for autoimmune diseases. Its pipeline includes anti-FcRn antibody candidates designed for subcutaneous administration.
Read more on IMVT →